While 90% of the PbA-infected mice became ECM-positive between day 6 and 8 post infection, only 40% of the anti-LFA-1 treated mice developed neurological signs; the remaining 60% survived the critical period of ECM development without any evidence for neurological impairment (Fig. 9A and B). This evidence concerns the gene ITGAL and infection.